<DOC>
	<DOCNO>NCT00118768</DOCNO>
	<brief_summary>This Phase II study conduct treatment-naive patient ( previous antiviral therapy Hepatitis C infection ) genotype-1 chronic hepatitis C evaluate safety effectiveness valopicitabine alone together Pegylated Interferon ( drug approve Food Drug Administration treatment Hepatitis C infection ) .</brief_summary>
	<brief_title>A Study Evaluate Combination Pegylated Interferon Alfa Plus Valopicitabine Patients With Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Documented clinical history genotype1 chronic Hepatitis C compensate liver disease Treatment Naive ( patient receive previous treatment chronic hepatitis C infection ) Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient coinfected HIV Hepatitis B Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Genotype-1 , Chronic Hepatitis C</keyword>
</DOC>